P95 Julius Clinical has become Akeura, a global specialist contract research organisation (CRO) with dual expertise in clinical and real-world settings. The launch of the Akeura brand stems from the successful integration that followed the 2025 merger of P95 and Julius Clinical.
Akeura supports sponsors across all phases of clinical development and real-world evidence (RWE), with an exclusive focus on neuroscience, infectious diseases and vaccines, and cardiometabolic diseases. As regulators increasingly turn to real-world data to inform decisions across the product lifecycle, the need to integrate clinical development and real-world expertise from the outset has never been greater, making Akeura’s launch particularly timely.
Akeura’s more than 500 researchers, clinicians, and scientists work across five continents and have delivered more than 1,000 studies, including over 600 clinical studies and 400 RWE projects, in more than 75 countries.
The company’s experience spans upward of 700,000 participants at over 5,000 sites, from pivotal therapeutic studies to population-scale vaccine research. That reach extends to hard-to-enroll populations worldwide, including Africa, where its teams have worked for more than 25 years, supported by specialized site networks and close site partnerships that bring studies closer to the participants they serve.
Behind those numbers is a model built around people. Akeura matches specialists to what each study requires, and the senior experts who shape the plan stay hands-on as the work unfolds. Key opinion leaders are part of that model, with practising physicians and leading researchers working within Akeura’s own teams and advisory networks to help shape study design from the earliest decisions.
